TG Therapeutics Inc (STU:NKB2)
€ 15.344 -0.116 (-0.75%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 76.77 PB Ratio: 16.30 GF Score: 73/100

TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 12:30AM GMT
Release Date Price: €20.15 (+10.17%)
Eric Joseph J.P. Morgan;Analyst

All right. Good afternoon. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is TG Therapeutics. And to present on behalf of the company is CEO, Mike Weiss. (Event Instructions)

Okay. With that, Mike?

Mike Weiss TG Therapeutics
Inc. - Chairman & CEO

Thanks, Eric, and thanks, everyone, for joining us. We have the honor to close out day two of the biotech JPM, I think, or at least Eric's team.

All right, so I'm going to get started here. First, I got to say big shout out to Blue, Michigan Wolverines, National Champions. I promise everyone that I put this on. So my daughters will be very pleased about this.

All right, so let's get going here. So I will be making some forward-looking statements. I usually say I may be making forward-looking statements. I will be making some forward-looking statements. For those of you who aren't, I do encourage you to review our public disclosure documents.

Okay, just a quick background before we get into some details.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot